Juergen Wolf
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 115
- Lung Cancer Diagnosis and Treatment 10
-
- Lymphoma Diagnosis and Treatment 47
- Co-authors
- Volker Diehl (49 shared papers)Roman Kurt Thomas (24 shared papers)Reinhard Buettner (15 shared papers)Daniel Ré (14 shared papers)Thomas Zander (21 shared papers)Heribert Bohlen (9 shared papers)Andrea Staratschek‐Jox (16 shared papers)Matthias Scheffler (19 shared papers)
- Journals
- Journal of Thoracic Oncology (23 papers)Journal of Clinical Oncology (15 papers)Annals of Oncology (14 papers)International Journal of Cancer (10 papers)Lung Cancer (9 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Juergen Wolf
265 papers receiving 24.6k citations
Juergen Wolf's Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 6.9k
- Pulmonary and Respiratory Medicine 9.4k
- Cancer Research 2.1k
- Pathology and Forensic Medicine 2.2k
- Molecular Biology 3.6k
Countries citing papers authored by Juergen Wolf
This map shows the geographic impact of Juergen Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Wolf more than expected).
Fields of papers citing papers by Juergen Wolf
This network shows the impact of papers produced by Juergen Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Wolf. The network helps show where Juergen Wolf may publish in the future.
Co-authors
The 25 scholars most cited alongside Juergen Wolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 280 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Comprehensive genomic profiles of small cell lung cancer Hit paper breakdown → | 2015 | 1840 |
| 2 | Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing Hit paper breakdown → | 2012 | 1528 |
| 3 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation Hit paper breakdown → | 2021 | 1362 |
| 4 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Hit paper breakdown → | 2015 | 1243 |
| 5 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Hit paper breakdown → | 2012 | 1163 |
| 6 | Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 743 |
| 7 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer Hit paper breakdown → | 2010 | 707 |
| 8 | Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 617 |
| 9 | Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Hit paper breakdown → | 2023 | 424 |
| 10 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 403 |
| 11 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Hit paper breakdown → | 2016 | 402 |
| 12 | Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer Hit paper breakdown → | 2011 | 400 |
| 13 | 2017 | 375 | |
| 14 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 357 |
| 15 | 2003 | 340 | |
| 16 | Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial Hit paper breakdown → | 2022 | 331 |
| 17 | Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort Hit paper breakdown → | 2015 | 313 |
| 18 | 2017 | 306 | |
| 19 | 2016 | 305 | |
| 20 | 2018 | 304 |
About Juergen Wolf
Juergen Wolf is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 280 papers that have together received 25.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (115 papers), Lymphoma Diagnosis and Treatment (47 papers), Lung Cancer Research Studies (17 papers), Cancer Immunotherapy and Biomarkers (14 papers), Viral-associated cancers and disorders (12 papers), Medical Imaging Techniques and Applications (11 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Palliative Care and End-of-Life Issues (6 papers). The work is most often cited by research in Oncology (6.9k citations), Pulmonary and Respiratory Medicine (9.4k citations), Cancer Research (2.1k citations), Pathology and Forensic Medicine (2.2k citations) and Molecular Biology (3.6k citations). Juergen Wolf has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Volker Diehl, Roman Kurt Thomas, Reinhard Buettner, Daniel Ré, Thomas Zander, Heribert Bohlen, Andrea Staratschek‐Jox, Matthias Scheffler, Ralf Küppers and Andreas Hans Scheel. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, International Journal of Cancer and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.